Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Wave Life Sciences
Biotech
GSK won't pick up Wave's genetic disease RNA editor
Wave plans to pursue accelerated approval for WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency.
Darren Incorvaia
Feb 2, 2026 11:14am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
20-year Novo vet lands first CEO role—Chutes & Ladders
May 30, 2025 8:30am
Wave's DMD drug remains on track in 48-week data
Mar 26, 2025 9:50am
Wave hails human RNA editing first for GSK-partnered prospect
Oct 16, 2024 10:22am
Takeda axes Huntington’s pact, freeing Wave to pursue partners
Oct 16, 2024 8:07am
